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Abstract
Background: Although diabetic patients have an increased rate of cardio-vascular events, there is considerable
heterogeneity with respect to cardiovascular risk, requiring new approaches to individual cardiovascular risk factor
assessment. In this study we used whole body-MR-angiography (WB-MRA) to assess the degree of atherosclerosis
in patients with long-standing diabetes and to determine the association between metabolic syndrome (MetS) and
atherosclerotic burden.
Methods: Long standing (≥10 years) type 1 and type 2 diabetic patients (n = 59; 31 males; 63.3 ± 1.7 years) were
examined by WB-MRA. Based on the findings in each vessel, we developed an overall score representing the
patient’s vascular atherosclerotic burden (MRI-score). The score’s association with components of the MetS was
assessed.
Results: The median MRI-score was 1.18 [range: 1.00-2.41] and MetS was present in 58% of the cohort (type 2
diabetics: 73%; type 1 diabetics: 26%). Age (p = 0.0002), HDL-cholesterol (p = 0.016), hypertension (p = 0.0008),
nephropathy (p = 0.0093), CHD (p = 0.001) and MetS (p = 0.0011) were significantly associated with the score.
Adjusted for age and sex, the score was significantly (p = 0.02) higher in diabetics with MetS (1.450 [1.328-1.572])
compared to those without MetS (1.108 [0.966-1.50]). The number of MetS components was associated with a
linear increase in the MRI-score (increase in score: 0.09/MetS component; r
2 = 0.24, p = 0.038). Finally, using an
established risk algorithm, we found a significant association between MRI-score and 10-year risk for CHD, fatal
CHD and stroke.
Conclusion: In this high-risk diabetic population, WB-MRA revealed large heterogeneity in the degree of systemic
atherosclerosis. Presence and number of traits of the MetS are associated with the extent of atherosclerotic burden.
These results support the perspective that diabetic patients are a heterogeneous population with increased but
varying prevalence of atherosclerosis and risk.
Introduction
Today diabetes mellitus is often classified as a coronary
heart disease (CHD) equivalent [1], which has signifi-
cantly influenced the guidelines for the treatment of dia-
betic complications over the last couple of years [2].
According to the American Diabetes Association (ADA),
all diabetic patients above 40 years of age should be
managed aggressively regarding risk factors with lipid
lowering and antiplatelet therapy, similar to patients
with a history of myocardial infarction [3]. Although the
term CHD equivalent focused attention on the increased
cardiovascular risk of diabetic patients, with coronary
heart disease being the leading cause of mortality
among people with diabetes [4], it is also obvious that
not all patients have the same risk [2,5,6]. Individualized
risk assessment could therefore lead to more appropriate
risk factor interventions [2,7]. Extensive research has
focused on the metabolic syndrome (MetS), a cluster of
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hyperglycemia, increased plasma triglycerides, decreased
HDL-cholesterol and hypertension, as a possible marker
for increased cardiovascular risk in diabetic patients [8].
Many studies have in fact found an association between
cardiovascular risk and MetS in type 2 [8-10] and some
also in type 1 diabetes [11,12], yet others have found
conflicting results in both types of diabetes [13,14].
Hence the MetS has become the center of an inten-
sive debate due to different and changing definitions,
lack of a unifying pathophysiological concept, disputed
predictive value regarding CHD and uncertain specific
therapeutic consequences [8,15,16]. While the joint
statement from the American Diabetes Association and
the European Association for the Study of Diabetes
(EASD) stated that the term MetS should not be used
as a diagnosis and that diabetes should be excluded
from the definition of the MetS since the presence of a
MetS seems to provide no additional predictive value
for cardiovascular complications or therapeutic conse-
quences in patients with diabetes [8], other still find
the MetS useful particularly for clinical purposes
[17-20].
Previously we have used whole-body magnetic
resonance angiography (WB-MRA) in patients with
long-standing type 1 or type 2 diabetes to obtain com-
prehensive vascular imaging (except coronaries) [21]. In
our study we found a high prevalence of occult athero-
sclerotic disease, demonstrating that the true extent of
atherosclerotic complications was largely underestimated
in these patients [21]. Furthermore, we developed a
score based on the WB-MRA findings representing the
atherosclerotic burden of each patient. In the current
s t u d yw eh a v ea n a l y z e dt h i sd a t at oa d d r e s st h ef o l l o w -
ing questions: 1. What is the variation of atherosclerotic
burden in patients with long-standing diabetes? 2. Is the
MetS associated with a high atherosclerotic score in
these patients? 3. Is the atherosclerosis detected by WB-
MRA associated with CHD and cardiovascular risk, esti-
mated with the United Kingdom Prospective Diabetes
Study (UKPDS) risk engine, an established risk algo-
rithm for diabetic patients?
Methods
Study population
The original study included 65 patients with type 1
(T1DM) or type 2 (T2DM) diabetes of more than 10
years which was published previously [21]. The para-
meters analyzed in this study were available for 59
patients of this population (28 females, 31 males). The
patients were enrolled over a 16 month period in our
Medical Department. The study was approved by the
ethics committee and all patients provided written con-
sent prior to their inclusion.
Inclusion criteria were diagnosis of type 1 or type 2
diabetes mellitus of >10 years duration. Exclusion cri-
teria were pregnancy, allergic reaction to Gadolinium-
chelates and a creatinine clearance <30 ml/min per 1.73
m
2 to avoid nephrogenic systemic fibrosis (NSF) [22].
Creatinine clearance was assessed using the Cockroft-
Gault formula.
At the time of inclusion, a number of parameters were
registered including age, sex, type and duration of dia-
betes, smoking history, body mass index (BMI), blood
pressure, HbA1c, triglycerides, low density lipoprotein
(LDL)-cholesterol, high density lipoprotein (HDL)-cho-
lesterol and creatinine. CHD status was assessed,
defined as documented history of myocardial infarction,
stenosis of >50% on coronary angiogram, coronary
intervention or bypass grafting. All patients received the
whole body MRI in the Department of Radiology within
3 months after recording the above mentioned
parameters.
The MetS was identified according to the definition of
the American Heart Association and the National Heart,
Lung, and Blood Institute (AHA/NHBLI) [17]: triglycer-
ides ≥150 mg/dl; HDL-cholesterol <40 mg/dl (male) or
<50 mg/dl (female); systolic blood pressure ≥130 mmHg
or diastolic blood pressure ≥85 mmHg or anti-hyperten-
sive medication, with the exception that BMI (>30 kg/
m
2) was used instead of waist circumference. MetS was
diagnosed when in addition to diabetes two or more of
these traits were present.
MRA
MR imaging studies were performed as described pre-
viously on a 1.5 T and 3 T whole body MR system
(Magnetom Avanto and Magnetom Tim Trio, Siemens
Medical Solutions, Erlangen, Germany) equipped with
32 receiver channels [21]. Twelve patients were scanned
at 1.5 T, 47 at 3 T after installation of the new MR
scanner. In brief, IPAT (integrated parallel acquisition
techniques) and a GRAPPA (generalized autocalibrating
partially parallel acquisitions) reconstruction algorithm
were used with acceleration factors between 2 and 3.
Various combinations of head and neck coils, spine
array coils and various body coils were employed (Sie-
mens Medical Solutions, Erlangen, Germany). All
patients received an intravenous injection of Omniscan®
(Gadodiamide, GE Healthcare).
First a time-of-flight (TOF)-MR angiogram of the cer-
ebral arteries with a spatial resolution of 0.7 × 0.5 × 0.7
mm was acquired. Then 3D-Gd-MR-angiography of the
carotids (resolution 1.0 × 1.0 × 1.0, iPAT factor 3), the
abdominal aorta (1.4 × 1.1 × 1.2, iPAT factor 3), the
thighs (1.1 × 1.1 × 1.1, iPAT factor 2), the calves and
pedal arteries (1.0 × 1.0 × 1.0, iPAT factor 2) was
obtained. The same scanning parameters and spatial
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CE-sequence of the lower calf and pedal arteries (1.4 ×
1.4 × 1.5, iPAT factor 3, temporal resolution 3.7 s/
frame) was performed after repositioning the patient in
order to compensate for a shortened range of table
movement in the Magnetom Trio and to increase diag-
nostic accuracy.
The MR exams of the diabetic group were evaluated
by two experienced radiologists who were blinded to all
clinical information, in a consensus reading. The cases
were presented in groups of five cases per reading ses-
sion in randomized order over a time period of four
weeks. MRA data sets were evaluated by multiplanar
reformats (MPR) and small volume maximum intensity
projections (thin MIP) for detection of stenosis as well
as volume-rendering (INSPACE) for detection of ana-
tomic variants. There were 22 segments analyzed and all
but the abdominal aorta and circle of Willis were bilat-
eral [23]. They included: 1) common carotid artery, 2)
internal extracerebral carotid artery, 3) intracerebral car-
otid artery/circle of Willis, 4) vertebral artery, 5) abdom-
inal aorta, 6) renal artery, 7) common iliac/femoral
artery, 8) internal iliac artery, 9) superficial femoral and
popliteal artery, 10) anterior tibial artery, 11) posterior
tibial artery and 12) peroneal artery.
As previously published we have created a new scor-
ing system for the degree of atherosclerotic disease bur-
den found in the diabetic patients, entitled the “vessel
score” [21]. The vessel score is determined as follows:
atherosclerotic lesions were quantified in each vessel by
a grading scheme using 6 levels ranging from normal to
occlusion with grade 1 = normal vessel without visible
changes or only mild wall irregularities, grade 2 = non
significant stenosis, grade 3 = singular significant steno-
sis exceeding 50% of diameter, grade 4 = multi-segmen-
tal significant stenoses with at least one exceeding 50%
of diameter, grade 5 = fading vessel with incomplete
visualization over the entire segment, grade 6 = com-
plete occlusion with (a) or without (b) reconstitution.
The sum of grades of all evaluated vessels divided by
the number of vessels resulted in an average vessel
score (average grade per evaluated vessel) representing
the patient’s vascular status.
Statistics
Continuous variables were described with mean ± stan-
dard deviation or median and range. Chi-squared tests
were used to test for simple associations between
dichotomous variables. Correlation between continuous
variables was tested with the Spearman rank correlation.
Differences between the mean were tested with a t-test.
A general linear model (GLM) was used to test for asso-
ciations between the score and other variables after
adjustment for age and sex. A p-value of <0.05 indicated
significance. SAS 9.1 was used for statistical evaluation.
Results
Fifty nine patients (31 males, 63 ± 13 years) with long
standing (>10 years, mean 20.7 years) type 1 (n = 19) or
type 2 (n = 40) diabetes were examined by MRA (Table
1). Prevalence rates of vascular lesions were 46% for per-
ipheral artery disease, 20% for cerebrovascular disease
and 8% for renal artery stenosis. The observed changes
are described in more detail in reference [21]. Typical
findings of vascular lesions are presented in figure 1.
T h er a n g eo ft h eM R I - s c o r ew a s1 . 0 0t o2 . 4 1w i t ha n
average score of 1.31 and a median of 1.18. In 22
patients the score was 1.00, indicating that these
patients had at most wall irregularities in all vessels
(Table 2).
In an unadjusted analysis, age, hypertension, low
HDL-cholesterol, MetS, CHD status and nephropathy
were significantly associated with the score, while
neither sex, diabetes duration, BMI, blood pressure, tri-
glycerides, LDL-cholesterol, creatinine, HbA1c,
Table 1 Study Population
Total Men Women
Type 1 Diabetes mellitus 19 (32%) 11 (35%) 8 (29%)
Type 2 Diabetes mellitus 40 (68%) 20 (65%) 20 (71%)
Age 63.3 ± 1.7 63.5 ± 2.4 63 ± 2.6
Diabetes duration 20.7 ± 1.4 20.4 ± 2.1 21 ± 1.7
Hypertension 51 (86%) 27 (87%) 22 (79%)
Systolic blood pressure 135 ± 2 133 ± 3 137 ± 3
Diastolic blood pressure 77 ± 1 76 ± 2 77 ± 2
Hyperlipoproteinemia 39 (66%) 19 (61%) 20 (71%)
Smoker 4 (7%) 3 (10%) 1 (4%)
BMI (kg/m
2) 27.8 ± 0.6 27.3 ± 0.6 28.3 ± 1.2
Coronary heart disease 22 (37%) 15 (48%) 7 (25%)
Cerebrovascular disease 11 (19%) 8 (26%) 3 (11%)
Peripheral artery disease 15 (25%) 10 (32%) 5 (18%)
Insulintherapy 51 (86%) 25 (81%) 26 (93%)
Oral antidiabetic drugs 21 (36%) 11 (35%) 10 (36%)
ACEI/ARB 43 (73%) 23 (74%) 20 (71%)
Lipid lowering drugs 36 (61%) 19 (61%) 17 (61%)
HbA1c (%) 7.3 ± 0.1 7.5 ± 0.2 7.1 ± 1.3
Creatinine (mg/dl) 1.2 ± 0.2 1.3 ± 0.2 1.1 ± 0.2*
LDL-Cholesterol (mg/dl) 101.9 ± 3.7 102.4 ± 5.1 101.3 ± 5.6
HDL-Cholesterol (mg/dl) 49.9 ± 1.9 47.2 ± 2.6 52.6 ± 2.8
Triglycerides (mg/dl) 181.0 ± 16.5 168.3 ± 18.3 195.1 ± 29.0
Parameters without a unit in brackets indicate number of patients (and
percentages).
Parameters with a unit in brackets are mean ± SEM
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor
blocker
LDL, low density lipoprotein; HDL, high density lipoprotein
* p < 0.05 vs. men
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with the score (Table 3).
MetS was present in 58% (n = 34) of the patients
(T2DM: 73%, n = 29; T1DM: 26%, n = 5) with no sex
difference. Patients without MetS were considerably
younger (56 ± 16 yr vs. 69 ± 8 yr). All patients with the
MetS had hypertension or anti-hypertensive medication
due to diagnosed hypertension, 26 had high triglycer-
ides, 22 had low HDL-cholesterol and 14 patients had a
BMI >30 kg/m
2. 14 Patients had 2 traits of the MetS,
1 2h a d3a n d8h a da l l4t r a i t s .1 8P a t i e n t sw i t h o u t
MetS still had 1 trait of the MetS, most often hyperten-
sion (n = 15).
Patients with MetS had a higher mean score than
those without MetS (1.450 [1.328-1.572] vs. 1.108
[0.966-1.250] respectively, p = 0.0002). This association
remained significant (p = 0.02) after adjustment for age
and sex. Furthermore, we found a dose-response rela-
tionship between the number of MetS components and
the MRA-score (increase in score: 0.09/MetS compo-
nent; r
2 = 0.24, p = 0.038 adjusted for age and sex, fig-
ure 2). Similar results were observed in the subgroup of
T2DM. After adjustment for age and sex T2DM patients
with MetS had a significantly higher mean score than
those without MetS (1.438 [1.297-1.580] vs. 1.130
[0.900-1.361] respectively, p = 0.03). In contrast, in
T1DM subjects, the score was only associated with the
presence of MetS in an unadjusted model. After adjust-
ment for age and sex the score was similar in T1DM
patients with and without MetS.
To further validate the MRA-score, we analyzed the
association of the score with cardiovascular risk calcula-
tions in T2DM patients, using the United Kingdom Pro-
spective Diabetes Study (UKPDS) risk engine [24].
Consistent with the significant association of score and
previously diagnosed CHD, a high score was signifi-
cantly associated with a high 10-year risk for CHD, fatal
CHD and stroke (Table 4).
Figure 1 MRA demonstrating typical atherosclerotic findings in patients with longstanding diabetes. A: moderate stenosis of the right
middle cerebral artery, B: severe right renal artery stenosis, C: advanced multisegmental bilateral peripheral artery disease.
Table 2 Distribution of score
Score Total Men Women
1.00 22 9 13
1.01-1.50 23 12 11
1.51-2.00 9 7 2
>2.00 5 3 2
Table 3 Unadjusted association with score
p-value
Age
a 0.0002
Sex
b 0.1082
Diabetes duration
a 0.9434
Hypertension
b 0.0008
Systolic BP
a 0.2233
Diastolic BP
a 0.731
LDL-cholesterol
a 0.2951
HDL-cholesterol
a 0.016
Triglycerides
a 0.0535
BMI
a 0.826
HbA1c
a 0.4529
MetS
b 0.0011
Creatinine
a 0.0601
CHD
b 0.0001
Retinopathy
b 0.0689
Neuropathy
b 0.6291
Nephropathy
b 0.0093
BP: blood pressure; CHD: coronary heart disease; MetS: metabolic syndrome;
a p-value refers to correlation coefficient;
b p-value refers to Wilcoxon test;
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During the last 10 years the classification of diabetes as a
CHD equivalent has helped to improve standards of dia-
betes care by underlining the importance of cardiovascular
risk factor management [3]. However, it is also obvious
that this simplified concept falls short of adequately
describing the true cardiovascular risk of a highly hetero-
geneous population [5,6]. The presence of the MetS, a
cluster of cardiovascular risk factors, may help to refine
risk factor assessment and treatment in diabetic patients.
In this study, 59 patients with long standing diabetes mel-
litus underwent whole body MRA with quantification of
atherosclerosis by determining an overall atherosclerosis
score. Using this score we investigated the degree of varia-
tion in macrovascular disease and found a significant asso-
ciation between the score and the presence of the MetS as
well as a dose-response relationship between the score
and the number of MetS-components.
Despite the general high risk of the population with an
average diabetes duration of 20.7 years and additional
cardiovascular risk factors in many patients, we found
very pronounced differences in the degree of athero-
sclerotic burden. The WB-MRA based score ranged
from 1.00 to 2.41 with a median of 1.18. More than one
third of the population (n = 22) had a score value of
1.00, indicating that these patients had no atherosclero-
tic changes or at most wall irregularities in all scanned
vessels. In contrast, all patients with a score above 2.0
(n = 5) had at least 3 completely occluded vessels and
several other stenotic lesions. These results are in line
with the perspective of diabetic patients as a heteroge-
neous population with increased but variable prevalence
of atherosclerosis and cardiovascular events [25,26].
In our study population a high score was significantly
associated with age, HDL-cholesterol, MetS and CHD
status. The number of components of the MetS was
associated with a linear increase in the MRI-score.
Furthermore, consistent with previous reports evaluating
MRI-based atherosclerosis scores [27,28], a high score
was significantly associated with estimated cardiovascu-
lar risk using an established risk algorithm.
Despite significant progress in recent years with
respect to risk factor modification particularly through
the use of lipid lowering agents and drugs targeting the
renin-angiotensin system [29], several studies have
found that there is still a large gap between guidelines
and clinical practice [30,31]. Furthermore, recent land-
mark studies aimed at investigating an even more
aggressive treatment of hyperglycemia, blood pressure
and dyslipidemia failed to show additional benefits in
diabetic patients [32,33]. A more individualized risk
assessment could hence allow clinicians to apply flexible
treatment goals to their diabetic patients and help to
focus their attention and resources on the patients most
at risk among the diabetic population [34]. Including
the well known concept of MetS into cardiovascular risk
assessment and treatment decisions may help to indivi-
dualize and further improve diabetes care.
There are several limitations to our study. First the
prognostic significance of the detected vascular lesions
is uncertain, due to the lack of follow up data. The asso-
ciation with the UKPDS risk calculations also must be
interpreted with caution since the risk engine is not vali-
dated for a diabetes duration of >20 years and has an
uncertain validity for patients with established cardiovas-
cular disease, although only patients with acute cardio-
vascular disease were excluded in the original UPKDS
study [35]. Furthermore, there was no examination of
the coronary arteries. However, cerebrovascular disease
and peripheral artery disease are both well established
predictors of cardiovascular mortality [26] and also in
this study, the score showed a strong association with
CHD status. Other limitations of this study are the rela-
tively small sample size and single on treatment
Figure 2 Number of components of the MetS is associated
with an increase in MRI-score (increase in score: 0.09/MetS
component; r
2 = 0.24, p = 0.038 adjusted for age and sex).
Data is presented as mean ± SEM.
Table 4 Correlation between MRA-score and
cardiovascular risk (UKPDS risk engine)
r p-value
CHD risk 0.46 0.0025
Fatal CHD risk 0.45 0.0036
Stroke risk 0.37 0.0204
Fatal stroke risk 0.29 0.073
r, Spearman correlation coefficient
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the statistical associations. Another limitation relates to
the scoring system. First of all, changes in all arteries
were treated equally. Thus, there was no “weighting” of
arteries (for example: changes of fibular arteries were
considered as relevant as those of carotid arteries). From
a clinical point of view, changes in some vascular beds
are obviously more relevant than changes in others.
However, a correct weighting of arteries is not possible.
Furthermore, the grading of the changes in the indivi-
dual arteries was considered to be linear, although this
is not the case. For example: “multi-segmental signifi-
cant stenoses with at least one exceeding 50% of the
vessel diameter” (grading 4) was considered to represent
double the amount of atherosclerosis as “non significant
stenosis” (grading 2). However, in order to create an
overall score for each patient, location and severity of
changes had to be described numerically.
Conclusion
In conclusion our results contribute further evidence to
the perspective of diabetic patients as a heterogeneous
population with increased but varying prevalence of car-
diovascular disease and risk. In our study, presence of
the Metabolic Syndrome and the number of its traits
helped to identify those patients with the largest athero-
sclerotic burden. Further research is needed to improve
the characterization of risk in diabetic patients and to
adapt the treatment guidelines to different risk classes.
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